ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2023 Earnings Conference Call September 14, 2022 10:30 AM ET

Company Participants

Jennifer Bath - President & CEO

Brad McConn - CFO

Ilse Roodink - Chief Scientific Officer

Barry Duplantis - VP, Client Relations

Operator

Good morning, and thank you for standing by. Welcome to ImmunoPrecise Antibodies First Quarter Fiscal 2022 Earnings Conference Call. Also on the call with us today are Jennifer Bath, Chief Executive Officer; Brad McConn, Chief Financial Officer; Ilse Roodink, Chief Scientific Officer; and Barry Duplantis, Vice President of Client Relations

Before we get started, remember, some statements we make today, may be considered forward-looking statements for the purpose of applicable United States and Canadian securities laws. IPA cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. IPA undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures may be used to help investors understand IPA's business performance. We refer current and potential investors to our forward-looking information section of its management discussion and analysis issued today at www.sedar.com, and on EDGAR at www.SEC.gov. Following our prepared remarks, we’ll answer analysts and investors’ submitted questions.

So, with that, I'll now turn the call over to Dr. Bath.

Jennifer Bath

Great. Thank you, Julianne. Good morning, everyone, and thank you for joining us today. We are pleased to offer Q1 updates on the heels of our year-end results, and as we enter this fiscal year with aggressive strategic aim, many of which we'll share with you today. We remain highly confident in our ability to grow revenues through new and existing clients, novel high revenue value - high-value revenue streams, and importantly, the commercialization of disruptive AI-driven in silico technologies, offered through our newest subsidiary, BioStrand. Additionally, four of our potential best-in-class and first-in-class therapies from our internal pipeline, are now positioned for active licensing, with the aim of commercialization this fiscal year. Lastly, we simultaneously prepare the regulatory submission of IPA’s four anti-SARS-CoV-2 antibody therapeutics, which have sailed through preclinical IND-enabling studies, and remain the only first-generation therapy to retain efficacy against all tested variants of concerns, including the most recently screened BA.2.75, with more details on that program to come on this call from Dr. Roodink.